Taylor Schwartz


Taylor Schwartz works collaboratively with clients to develop, design, and execute epidemiological and health economics and outcomes research studies in a variety of therapeutic areas, in addition to healthy policy analyses and medical innovation value assessment studies.

Taylor’s expertise is in epidemiological methods, survey research methods, health policy, and value assessment and frameworks. Prior to joining Avalere, Taylor was a senior research scientist at Precision Health Economics where he conducted health economics research focused on estimating the value of innovative health technologies and examining the impact of policy changes on innovation and population health. He has also worked at Tufts University School of Medicine and the University of California, San Francisco, performing research on chronic and infectious diseases, substance misuse, adolescent risk behaviors, and mental health. He currently holds an adjunct appointment at American University and has held past adjunct appointments at the University of North Carolina, Chapel Hill, Gillings School of Global Public Health; San Francisco State University’s Health Education Department; the University of San Francisco's Politics Department; San Jose State University; and the University of New England, where he taught a variety of courses, including epidemiology, public health, biostatistics, health policy, and research methods.

Taylor received his MPH in epidemiology and biostatistics from Tufts University School of Medicine. He also received his BA in community health and American studies from Tufts University.

Authored Content

Avalere analyzed the top trends in HEOR and key implications for life sciences companies to consider for future strategic planning.

Avalere experts dive into Trend #8: HEOR as a Differentiator vs. a Commodity and explore the need for tailored evidence generation planning.

In the next installment of our 2023 Top Trends in HEOR series, Avalere experts dive into Trend #8: HEOR as a Differentiator Versus a Commodity.

ICER recently proposed piloting the GRACE framework in place of traditional cost-effectiveness analysis. We review the background of GRACE and its implications.

Avalere identified the top trends in HEOR and key implications for life sciences companies to consider for their 2024 strategic plans.

Avalere identified the top trends in health economics and outcomes research in 2023 and beyond. In this video, Avalere experts dive into a few of the key trends in HEOR that are significantly shaping the landscape.

As the US value assessment landscape evolves, a new third-party framework may standardize requirements and open reimbursement pathways for digital health.

Manufacturers should reevaluate CMS engagement strategies as soon as possible to maximize the opportunity to influence the IPAY 2026 Medicare negotiations.

Avalere assessed the current use of patient-centered outcomes in ICER evidence reports and determined the patient voice minimally influences modeling results.

ICER announced proposed changes to its Value Assessment Framework. Stakeholders have limited time to review and comment by June 30.

Manufacturers of therapeutic alternatives to negotiation-eligible drugs should examine their value and evidence strategy in response to new dynamics.

Current value assessment methods do not effectively and quantitatively include patients’ perspectives in the evaluation of treatment value.

Avalere was pleased to partner with the nutrition community to develop and test the Global Malnutrition Composite Score, which has now received conditional support from the Measure Applications Partnership (MAP)—pending endorsement by the National Quality Forum (NQF)—for inclusion in the Hospital Inpatient Quality Reporting (IQR) Program.